BXP
NEUTRALBeximco Pharma Requests Extension to Publish Q1 Results
The pharmaceutical company has requested an extension to publish its first quarter financial results for the period ended 30 September 2025.
Beximco Pharmaceuticals .
43.95GBX
2.21%
Market Cap
268.68M
Volume
17.92k
37% of avg
P/E Ratio
5.40
EPS (TTM)
8.14
Beta
0.17
Day Range
43.11p - 44.00p
52 Week Range
31.55p43.95p52.33p
43.95p
Upcoming Events
March 2026
Triko generic available for purchase and supply
High Impact Event
BXP
NEUTRALBeximco Pharmaceuticals Changes Name to Beximco Pharmaceuticals PLC
The pharmaceutical company has announced it is changing its name to Beximco Pharmaceuticals PLC, effective November 5, 2025.
BXP
NEUTRALBeximco Pharma Requests Extension to Publish 2025 Results
The pharmaceutical company has requested an extension to publish its financial results for the year ended 30 June 2025 due to an ongoing legal dispute regarding the appointment of additional independent directors.
BXP
NEUTRALBeximco Pharma announces affordable generic treatment for cystic fibrosis
The pharmaceutical company has partnered to launch a generic version of a lifesaving cystic fibrosis treatment at a significantly lower price than the branded product.
BXP
NEUTRALBeximco Pharma Provides Update on BSEC Order
The pharmaceutical company provides an update on the ongoing High Court hearing regarding the BSEC's proposed appointment of additional independent directors to the Board.
BXP
NEUTRALBeximco Pharma Requests Extension to Publish Q3 Results
The pharmaceutical company has requested an extension to publish its Q3 financial results due to an ongoing legal matter regarding the appointment of additional independent directors.
BXP
NEUTRALBeximco Pharma Denies Corruption Allegations, Provides Update on Regulatory Order
The pharmaceutical company denies allegations of corruption in Covid-19 vaccine procurement and provides an update on a regulatory order regarding its board of directors.
BXP
NEUTRALBeximco Pharma Faces Regulatory Uncertainty Over Board Appointments
The pharmaceutical company faces regulatory uncertainty over the proposed appointment of additional independent directors to its board, with a court decision expected by mid-March.
BXP
NEUTRALBeximco Pharma Announces Board Change
The pharmaceutical company has announced a change in its Board of Directors, with a new Non-Executive Director nominated by a major shareholder.
BXP
GOODBeximco Pharmaceuticals Reports Strong Half-Year Results with 17.5% Profit Growth
The generic drug manufacturer reported an 8.8% increase in net sales and a 17.5% rise in profit after tax for the half-year. Export sales surged by 31.6%, with expansion into new markets.